Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageWe are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields that exert physical forces to kill cancer cells. Our therapy is delivered through a medical device. Our key priorities are to drive commercial adoption of Optune Gio®, Optune Lua®, and Optune Pax®, our commercial TTFields therapy devices, obtain regulatory approval to market TTFields therapy devices in new indications, such as brain metastases from non-small cell lung cancer ("NSCLC"), and to advance clinical and product development programs intended to extend overall survival in some of the most aggressive forms of cancer.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q2 2026 · $165.4MThe company’s own SEC segment disclosure.
- United States$103.0M62%
- Germany$23.3M14%
- France$21.3M13%
- Japan$11.8M7%
- China$6.0M4%
NovoCure Limited (NVCR) reported revenue of $174M in Q1 2026 (quarter ended March 31, 2026), up 12% from the same quarter a year earlier. That came with a gross margin of 78% and net loss of $71M. For the full year FY2025, revenue was $655M (+8.3% year on year) and net income −$136M. Its largest region in 2026-Q2 was United States at $103M, 62% of the disclosed total, just ahead of Germany at 14%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.